RxDoctor Payments Data

James Perschbacher, MD

Cardiovascular Disease · Saint Louis, MONPI 1417044777

Payments from drug & device makers

$924in general payments, 2019–2025

Across 35 payments — averaging $26.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jenavalve Technology, Inc.$171
  • Sanofi-aventis U.S. LLC$150
  • Abiomed$119
  • Novartis$116
  • Pfizer$81
  • Johnson & Johnson$72
  • plus $216 from 10 others

What the payments were for

  • Consulting fees$17119%
  • Food & beverage$75381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$924 in reported general payments places this provider in the 35th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$178,873
Medicare patients
1,688
Services billed
2,841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban899$917,371
XareltoRivaroxaban247$221,862
EntrestoSacubitril/Valsartan174$192,186
MultaqDronedarone Hcl104$168,282
Repatha SureclickEvolocumab166$133,635
JardianceEmpagliflozin116$98,146
FarxigaDapagliflozin Propanediol87$86,045
Praluent PenAlirocumab24$13,885
Rosuvastatin Calcium712$8,894
Ezetimibe338$7,200
Metoprolol Succinate556$7,182
Dabigatran EtexilateDabigatran Etexilate Mesylate17$7,067
Atorvastatin Calcium658$6,487
Diltiazem 24hr Er (Cd)Diltiazem Hcl122$5,083
Torsemide258$4,476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$81$917,371899 claims
Johnson & JohnsonXarelto$72$221,862247 claims
NovartisEntresto$116$192,186174 claims
Sanofi-aventis U.S. LLCMultaq$150$168,282104 claims
Boehringer IngelheimJardiance$21$98,146116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →